Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Social Media
Natural Disasters
Unemployment
Stock Markets
European Union
Taxes
World Cup
Work
Senate
Kremlin
Education
Published • loading... • Updated

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Summary by cancernetwork.com
The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
cancernetwork.comcancernetwork.com

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.

Read Full Article
targetedonc.comtargetedonc.com

Nivolumab Plus Ipilimumab Sets New Standard of Care in MSI-H/dMMR mCRC

Nivolumab plus ipilimumab shows durable survival benefit over chemotherapy and monotherapy in mismatch repair-deficient colorectal cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Saturday, May 31, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cancer

Cancer

News
For You
SearchBlindspotLocal